CD Markers, Translocations, and Targeted Therapies in Lymphoid and Myeloid Neoplasms
For B-cell lymphomas, prioritize CD19 and CD20 as therapeutic targets with bispecific T-cell engagers (mosunetuzumab, epcoritamab, glofitamab) and monoclonal antibodies, while for myeloid malignancies, target selection remains challenging due to shared expression with normal hematopoietic cells, requiring careful antigen selection to avoid myelotoxicity.
B-Cell Lymphomas: CD Markers and Targeted Therapies
Key Immunophenotypic Markers
- CD19: Universal B-cell marker, target for CAR-T and bispecific antibodies
- CD20: Expressed on mature B-cells, primary target for therapeutic antibodies
- CD10: Germinal center marker (positive in follicular lymphoma, some DLBCL)
- CD79a: B-cell lineage marker
- Cytoplasmic CD22: B-cell specific marker
Approved Bispecific T-Cell Engagers for B-Cell Lymphomas
CD20 × CD3 Bispecific Antibodies 1, 2:
- Mosunetuzumab - Approved for follicular lymphoma (FL) as third-line therapy
- Glofitamab - Approved for diffuse large B-cell lymphoma (DLBCL) as third-line therapy
- Epcoritamab - Approved for both FL and DLBCL as third-line therapy
- Odronextamab - Approved for FL and DLBCL (EU only) as third-line therapy
All four agents show CRS in approximately 50% of patients, predominantly low-grade, with ICANS incidence below 10% 2.
CD19-Directed Therapies 1:
- CAR-T cells: Axicabtagene ciloleucel, tisagenlecleucel, lisocabtagene maraleucel (for relapsed/refractory FL after ≥2 prior therapies)
- Monoclonal antibody: Tafasitamab + lenalidomide + rituximab
- Antibody-drug conjugate: Loncastuximab tesirine + rituximab
Mantle Cell Lymphoma Specific Therapy
Zanubrutinib + obinutuzumab - BTK inhibitor-based regimen particularly effective for TP53-mutated classical MCL 1
Acute Myeloid Leukemia: Markers and Translocations
Critical Diagnostic Markers 3
Myeloid Lineage Assignment:
- Myeloperoxidase (MPO) - definitive myeloid marker
- Monocytic markers (requires ≥2): CD11c, CD14, CD64, lysozyme, nonspecific esterase
Key Recurrent Translocations and Treatment Implications 3:
t(8;21)(q22;q22) - AML with RUNX1-RUNX1T1
- Diagnosis of AML regardless of blast count
- Generally favorable prognosis
inv(16)(p13.1q22) or t(16;16)(p13.1;q22) - AML with CBFB-MYH11
- Diagnosis of AML regardless of blast count
- Favorable prognosis
t(15;17)(q22;q12) - Acute promyelocytic leukemia with PML-RARA
- Target therapy: All-trans retinoic acid (ATRA) + arsenic trioxide
- Diagnosis of AML regardless of blast count
- Variant RARA translocations may show ATRA resistance
t(9;11)(p22;q23) - AML with MLLT3-MLL
- Requires ≥20% blasts for AML diagnosis
- Specify other MLL translocations separately
t(6;9)(p23;q34) - AML with DEK-NUP214
- Poor prognosis entity
inv(3)(q21q26.2) or t(3;3)(q21;q26.2) - AML with RPN1-EVI1
- Poor prognosis
t(1;22)(p13;q13) - Megakaryoblastic AML with RBM15-MKL1
- Occurs in infants
Molecular Mutations with Therapeutic Implications 3
- NPM1 mutation - Provisional AML entity, generally favorable if FLT3-ITD negative
- CEBPA mutation - Provisional AML entity, favorable prognosis
- FLT3 mutations - Strongly recommended testing in all cytogenetically normal AML
- FLT3 inhibitors available for treatment 4
Chronic Myeloid Leukemia: BCR-ABL1 and TKI Therapy
t(9;22)(q34;q11.2) - Philadelphia chromosome with BCR-ABL1 fusion 4
Tyrosine Kinase Inhibitors:
- First-generation: Imatinib
- Second-generation: Dasatinib, nilotinib, bosutinib
- Third-generation: Ponatinib (for T315I mutation)
Specific dosing not provided in guidelines; refer to individual drug labels for precise dosing based on disease phase and tolerance.
Mixed Phenotype Acute Leukemia (MPAL) Diagnostic Criteria 3
Lineage Assignment Requirements:
- Myeloid: MPO positive OR ≥2 monocytic markers (CD11c, CD14, CD64, lysozyme)
- T-lineage: Cytoplasmic CD3 (definitive) OR surface CD3
- B-lineage: Strong CD19 + ≥1 of (CD79a, cytoplasmic CD22, CD10) OR weak CD19 + ≥2 of these markers strongly expressed
T-Cell and NK-Cell Neoplasms 5
Key Diagnostic Translocations
t(14;14)/inv(14) or t(X;14) - T-cell prolymphocytic leukemia
- Present in 95% of cases
- Integral to diagnosis
ALK gene translocations - Anaplastic large cell lymphoma
- Defines ALK-positive subtype
- Better prognosis than ALK-negative
Recurrent Genetic Alterations
- Tumor suppressor losses: SETD2, CDKN2A, TP53
- Oncogene gains: MYC
- Pathway mutations: JAK-STAT, RAS activation
Plasmacytoid Dendritic Cell Neoplasm 3
Immunophenotype (formerly "blastic NK-cell lymphoma"):
- Positive: CD4, CD43, CD56, CD123, BDCA-2/CD303, TCL1, CLA
- Variable: CD7, CD33 (common), TdT (30%)
- Negative: MPO, CD34, CD117, nonspecific esterase
Practical Algorithmic Approach to Distinguish Entities
Step 1: Determine Lineage
- MPO positive → Myeloid lineage
- Cytoplasmic CD3 positive → T-lineage
- CD19 + CD79a/CD22/CD10 → B-lineage
- Multiple lineage markers → Consider MPAL using criteria above
Step 2: Identify Specific Entity
For B-cell neoplasms:
- CD10+ with t(14;18) → Follicular lymphoma
- CD20+ large cells → DLBCL (check for CD3×CD20 bispecific eligibility)
- Cyclin D1+ → Mantle cell lymphoma (test TP53 for BTK inhibitor consideration)
For myeloid neoplasms:
- Check for recurrent translocations (t(8;21), inv(16), t(15;17)) → Defines AML subtype
- If cytogenetically normal → Test NPM1, CEBPA, FLT3
- t(9;22) → CML (initiate TKI therapy)
Step 3: Select Targeted Therapy
B-cell lymphomas (relapsed/refractory after ≥2 lines) 1:
- CD20+ → CD20×CD3 bispecific (mosunetuzumab, epcoritamab, glofitamab, odronextamab)
- CD19+ → CAR-T cells OR tafasitamab combinations OR loncastuximab tesirine
- TP53-mutated MCL → Zanubrutinib + obinutuzumab
AML:
- t(15;17) → ATRA + arsenic trioxide (curative intent)
- FLT3-mutated → FLT3 inhibitors 4
- Gemtuzumab ozogamicin (only FDA-approved antibody for AML) 6
Critical Pitfalls and Caveats
Myeloid malignancy targeting challenges 6, 7:
- Absence of AML-specific surface antigens creates on-target/off-leukemia toxicity risk
- Normal hematopoietic cells share most myeloid markers with blasts
- Bispecific antibodies for AML remain investigational with limited success compared to lymphoid malignancies
- Antigen heterogeneity and immunosuppressive microenvironment limit solid tumor and some myeloid applications 8
Bispecific antibody toxicity management 2:
- CRS mitigation strategies vary by agent; step-up dosing commonly employed
- ICANS risk lower than CAR-T but requires monitoring
- Infections, hypogammaglobulinemia, and cytopenias are common with continuous dosing 9
Resistance mechanisms 9:
- T-cell exhaustion with prolonged exposure
- Antigen loss or downregulation
- Soluble target antigens (e.g., soluble BCMA in myeloma)
- Extramedullary disease progression